ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

The high costs associated with allergy immunotherapy can hamper the global allergy immunotherapy market growth. Immunotherapy requires long-term commitment from patients as it involves years of regularly scheduled visits to the doctor's office for getting injections or pills. This prolonged treatment duration drastically increases the overall therapy costs. Moreover, each allergy immunotherapy prescription is custom-made for each individual patient based on their specific allergens. This customized production in a low volume adds to the per patient therapy costs.

Market Opportunities: Increasing Research and Development Activities by Key Market Players

Increasing research and development activities by market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in August 2023, Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis. The phase 1/1b trial is a randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-2004 in healthy volunteers and participants with allergic rhinitis (AR).